CVS Health Corporation $CVS Shares Purchased by Rhumbline Advisers

Rhumbline Advisers lifted its stake in shares of CVS Health Corporation (NYSE:CVS) by 0.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,398,761 shares of the pharmacy operator’s stock after buying an additional 8,598 shares during the quarter. Rhumbline Advisers owned about 0.19% of CVS Health worth $180,842,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CVS. Vanguard Group Inc. boosted its stake in CVS Health by 1.7% in the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after acquiring an additional 2,063,737 shares in the last quarter. State Street Corp lifted its holdings in shares of CVS Health by 1.4% in the 2nd quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after purchasing an additional 800,414 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of CVS Health by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock valued at $1,966,083,000 after purchasing an additional 675,824 shares during the period. Invesco Ltd. grew its stake in CVS Health by 15.3% during the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after buying an additional 3,118,626 shares during the last quarter. Finally, Norges Bank acquired a new position in CVS Health during the second quarter worth approximately $1,358,698,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

CVS Health stock opened at $75.54 on Wednesday. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. CVS Health Corporation has a 12 month low of $54.06 and a 12 month high of $85.15. The company has a market cap of $95.89 billion, a price-to-earnings ratio of 198.79, a price-to-earnings-growth ratio of 0.70 and a beta of 0.50. The stock’s 50-day moving average is $78.52 and its 200-day moving average is $75.98.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. CVS Health’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio is 700.00%.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 revenue and adjusted EPS beat expectations — total revenue rose ~8.2% to $105.7B and adjusted EPS came in at $1.09, supporting the view that CVS’s turnaround is gaining traction. Read More.
• Positive Sentiment: Operational improvements: CVS completed a shift to cost‑based pharmacy reimbursement and reports improved prior‑authorization performance at Aetna — items that should help margins and predictability over time. Read More.
• Neutral Sentiment: Analyst tone is mixed but not uniformly negative — firms like Argus note pressure from Medicare proposals while retaining a favorable view of CVS’s long‑term positioning. Read More.
• Negative Sentiment: Medicare rate concerns: management called the 2027 Medicare Advantage rate notice “disappointing,” and ongoing Medicare proposal risks could compress MA margins and investor sentiment. This was a key reason shares weakened despite the beat. Read More.
• Negative Sentiment: Profit/guidance headwinds: while revenue was a record, some metrics disappointed — reports flagged lower full‑year profit vs. certain Street expectations, a lowered cash‑flow outlook in some commentary, and management provided an EPS range that some investors viewed as conservative, contributing to pre‑market weakness. Read More.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CVS. Leerink Partners increased their price objective on CVS Health from $86.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Bank of America decreased their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of CVS Health in a research report on Wednesday, December 10th. Barclays upped their target price on shares of CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. raised their price target on CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Nineteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $94.82.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.